Application of Nano Biomaterials in Antiviral Vaccine Adjuvant

doi:10.19894/j.issn.1000-0518.210062

Chinese Journal of Applied Chemistry ›› 2021, Vol. 38 ›› Issue (5): 572-581.DOI: 10.19894/j.issn.1000-0518.210062

• Review • Previous Articles Next Articles

Application of Nano Biomaterials in Antiviral Vaccine Adjuvant

CAO Ling-Zhi¹, WANG Zhao-Shuo¹, WANG Bei^2*

¹College of Chemistry & Environmental Science Hebei University, Chemical Biology Key Laboratory of Hebei Province, Key Laboratory of Medicinal Chemistry and Molecular Diagnosis Ministry of Education , Baoding 071002, China
²College of Basic Medical Science,Hebei University, Baoding 071002, China

Received:2021-02-05 Accepted:2021-03-21 Published:2021-05-01 Online:2021-07-01
Supported by:
Supported by Beijing-Tianjin-Hebei Cooperation Fundamental Research Project (No.19JCZDJC64100)

Abstract

Abstract: Viral infectious diseases seriously endanger human health, the new type of coronary pneumonia has become a major global public safety and health incident. Vaccination is an important way to effectively prevent and control viral infections and the spread of infectious diseases. While routine vaccines have shown a shortfall, such as short half-life, weak immunogenicity, weak targeting, slow absorption, and high storage and delivery requirements. In recent years, nanobiomaterials are expected to be used as vaccine adjuvants for the prevention and treatment of viral infectious diseases due to their lower systemic toxicity, stronger tissue targeting, higher specific surface area and lower immune titer. This review will focus on the classification, action pathways and mechanisms of nanobiomaterials as adjuvants for antiviral vaccines. In addition, the application of nanobiomaterials in the new crown vaccine is described in combination with coronavirus disease-19 (COVID-19), which is currently popular worldwide. Finally, the challenges faced by nanobiomaterials in antiviral vaccine adjuvants are summarized.

Key words: Nano-biomaterials, Adjuvants of vaccine, Antiviral, COVID-19

CLC Number:

O641.3

CAO Ling-Zhi, WANG Zhao-Shuo, WANG Bei. Application of Nano Biomaterials in Antiviral Vaccine Adjuvant[J]. Chinese Journal of Applied Chemistry, 2021, 38(5): 572-581.

References

[1] BAYLAC P B. Vaccine development and collaborations: lessons from the history of the meningococcal A vaccine (1969-73)[J]. Med Hist, 2019, 63(4): 435-453.
[2] 林颐. 难以平息的战争: 瘟疫与人——读《疫苗的史诗》[J]. 青春期健康, 2020(6): 68-69.
LIN Y. An unquenchable war: the plague and people——reading “the epic of vaccines”[J]. Adolesc Health, 2020(6): 68-69.
[3] ROBISON H L, HUNT L A , WEBSTER R G. Protection against a lethal influenza virus challenge by immunization with a hae mag glutinin-expressing plasmid DNA[J]. Nature, 1994, 12: 957-960.
[4] SABORNI C, CHEN J Y, HUI W C, et al. Nanoparticle vaccines adopting virus-like features for enhanced immune potentiation[J]. Nanotheranostics, 2017, 1(3): 244-260.
[5] VARTAK A, SUCHECK S J. Recent Advances in subunit vaccine carriers[J]. Vaccines, 2016, 4(2).
[6] YENKOIDIOK D L, JEWELL C M. Integrating biomaterials and immunology to improve vaccines against infectious diseases[J]. ACS Biomater Sci Eng, 2020, 6(2): 759-778.
[7] 黄帅. 基于纳米颗粒(MOF53)的鱼用候选疫苗的研究[D]. 海南大学, 2019.
HUANG S. Research on candidate vaccines for fish based on nanoparticles (MOF53) [D]. Hainan University, 2019.
[8] ZHU M, WANG R, NIE G. Applications of nanomaterials as vaccine adjuvants[J]. Hum Vaccines Immunother, 2014, 10(9): 2761-2774.
[9] PEEK L J, MIDDAUGH C R, BERKLAND C. Nanotechnology in vaccine delivery[J]. Adv Drug Delivery Rev, 2008, 60(8): 915-928.
[10] TAO W, HURST B L, SHAKYA A K, et al. Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses[J]. Antiviral Res, 2017, 141: 62-72.
[11] TENG Z, SUN S, CHEN H, et al. Golden-star nanoparticles as adjuvant effectively promotes immune response to foot-and-mouth disease virus-like particles vaccine[J]. Vaccine, 2018, 36(45): 6752-6760.
[12] SANCHEZ G D,GUEN P L, VILLERET B, et al. Silver nanoparticle-adjuvanted vaccine protects against lethal influenza infection through inducing BALT and IgA-mediated mucosal immunity[J]. Biomaterials, 2019, 217: 119308.
[13] JIN X H, ZHENG L L, SONG M R, et al. A nano silicon adjuvant enhances inactivated transmissible gastroenteritis vaccine through activation the toll-like receptors and promotes humoral and cellular immune responses[J]. Nanomedicine, 2018, 14(4): 1201-1212.
[14] LV H, YUAN Y, XU Q, et al. Carbon quantum dots anchoring MnO₂/graphene aerogel exhibits excellent performance as electrode materials for supercapacitor[J]. J Power Sources, 2018, 398: 167-174.
[15] SOARES D C F, SOARES L M, GOES A M, et al. Mesoporous SBA-16 silica nanoparticles as a potential vaccine adjuvant against Paracoccidioides brasiliensis[J].Micropor Mesopor Mater, 2020, 291: 109676.
[16] 孙建宏. 免疫佐剂的研究进展[J]. 黑龙江畜牧兽医, 1998(2): 40-42, 49.
SUN J H. Research progress of immune adjuvants[J]. Heilongjiang Xumu Shouyi, 1998(2): 40-42, 49.
[17] 王宁, 邱倡, 陈敏囡, 等. 被覆生物相容材料的氧化铝纳米粒:一种高效率亚单位疫苗佐剂-传递系统(英文)[C]. 中国生物工程学会第十三届学术年会暨2019年全国生物技术大会论文集, 2019.
WANG N, QIU C, CHEN M N, et al. Alumina nanoparticles coated with biocompatible materials: a high-efficiency subunit vaccine adjuvant-delivery system (English)[C]. The 13th academic year of the Chinese society of bioengineering conference and proceedings of the 2019 national biotechnology conference, 2019.
[18] BILYY R, PARYZHAK S, TURCHENIUK K, et al. Aluminum oxide nanowires as safe and effective adjuvants for next-generation vaccines[J]. Mater Today, 2019, 22: 58-66.
[19] ABDELALLAH N H, GABER Y, RASHED M E, et al. Alginate-coated chitosan nanoparticles act as effective adjuvant for hepatitis A vaccine in mice[J]. Int J Biol Macromol, 2020, 152: 904-912.
[20] BOOKSTAVER M L, TSAI S J, BROMBERG J S, et al. Improving vaccine and immunotherapy design using biomaterials[J]. Trends Immunol, 2018, 39(2):135-150.
[21] YYENKOIDIOK D L, JEWELL C M. Integrating biomaterials and immunology to improve vaccines against infectious diseases[J]. ACS Biomater Sci Eng, 2020, 6(2): 759-778.
[22] PAN J, CUI Z. Self assembled nanoparticles: exciting platforms for vaccination[J]. Biotechnol J, 2020, 15(12): 2000087.
[23] RICHNER J M, HIMANSU S, DOED K A, et al. Modified mRNA vaccines protect against Zika virus infection[J]. Cell, 2017, 168(6): 1114-1125.
[24] MALEKI A, HASSANZADEH A F, VARZI Z, et al. Magnetic dextrin nanobiomaterial: an organic-inorganic hybrid catalyst for the synthesis of biologically active polyhydroquinoline derivatives by asymmetric Hantzsch reaction[J]. Mater Sci Eng, C, 2019, 109:110502.
[25] MANOLOVA V, FLACE A, BAUER M, et al. Nanoparticles target distinct dendritic cell populations according to their size[J]. Eur J Immunol, 2008, 38(5): 1404-1413.
[26] BUONAGURO L, PETRIZZO A, TORNESELLO M L, et al. Translating tumor antigens into cancer vaccines[J]. Clin Vaccine Immunol, 2011, 18(1): 23-34.
[27] FENTON O S, OLAFSON K N, PLIIAI P S, et al. Advances in biomaterials for drug delivery[J]. Adv Mater, 2018: e1705328.
[28] HAYAT S M G, DARROUDI M. Nanovaccine: a novel approach in immunization[J]. J Cell Physiol, 2019, 234(8): 12530-12536.
[29] HU Y, SMITH D, ZHAO Z, et al. Alum as an adjuvant for nanoparticle based vaccines: a case study with a hybrid nanoparticle-based nicotine vaccine[J]. Nanomedicine, 2019, 20: 102023.
[30] JIN Z, LI W, CAO H, et al. Antimicrobial activity and cytotoxicity of N-2-HACC and characterization of nanoparticles with N-2-HACC and CMC as a vaccine carrier[J]. Chem Eng J, 2013, 221: 331-341.
[31] GIANVINCENZO P D, CALVO J, PEREZ S, et al. Negatively charged glyconanoparticles modulate and stabilize the secondary structures of a gp120 V3 loop peptide: toward fully synthetic HIV vaccine candidates[J]. Bioconjugate Chem, 2015, 26(4): 755-765.
[32] LI S, YANG Y, LIN X, et al. Biocompatible cationic solid lipid nanoparticles as adjuvants effectively improve humoral and T cell immune response of foot and mouth disease vaccines[J]. Vaccine, 2020, 38(11): 2478-2486.
[33] MARTINS K, COOPER C L, STRONSKY S M, et al. Adjuvant-enhanced CD4 T cell responses are critical to durable vaccine immunity[J]. EBioMedicine, 2016, 3: 67-78.
[34] CLIMENT N, MUNIER S, et al. Loading dendritic cells with PLA-p24 nanoparticles or MVA expressing HIV genes induces HIV-1-specific T cell responses[J]. Vaccine, 2014, 32(47): 6266-6276.
[35] GU P, WUSIMAN A, ZHANG Y, et al. Polyethylenimine-coated PLGA nanoparticles-encapsulated Angelica sinensis polysaccharide as an adjuvant for H9N2 vaccine to improve immune responses in chickens compared to Alum and oil-based adjuvants[J]. Vet Microbiol, 2020, 251: 108894.
[36] KINGHT F C, GILCHUK P, KUMARUMAR A, et al. Mucosal immunization with a pH-responsive nanoparticle vaccine induces protective CD8(+) lung-resident memory T cells[J]. ACS Nano, 2019, 13(10): 10939-10960.
[37] HUANG Y, NAN L, XIAO C, et al. Optimum preparation method for self-assembled PEGylation nano-adjuvant based on rehmannia glutinosa polysaccharide and its immunological effect on macrophages[J]. Int J Nanomed, 2019, 14: 9361-9375.
[38] MENG H, LEONG W, LEONG K W, et al. Walking the line: the fate of nanomaterials at biological barriers[J]. Biomaterials, 2018, 174: 41-53.
[39] QIAO D, LIU L, CHEN Y, et al. Potency of a scalable nanoparticulate subunit vaccine[J]. Nano Lett, 2018, 18(5): 3007-3016.
[40] HANSON M C, CRESPO M P, ABRAHAM W, et al. Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants[J]. J Clin Invest, 2015, 125(6): 2532-2546.
[41] WANG W, ZHOU X, BIAN Y, et al. Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B[J]. Nat Nanotechnol, 2020, 15(5): 406-416.
[42] WILSON J T. A sweeter approach to vaccine design[J]. Science, 2019, 363(6427): 584-585.
[43] CROMMELIN D J A, VAN H P, STORM G. The role of liposomes in clinical nanomedicine development. what now? now what?[J]. J Controlled Release, 2020, 318: 256-263.
[44] COVID-19 therapies and vaccine landscape[J]. Nat Mater, 2020, 19(8): 809.
[45] SHIN M D, SHUKLA S, CHUNG Y H, et al. COVID-19 vaccine development and a potential nanomaterial path forward[J]. Nat Nanotechnol, 2020, 15(8): 646-655.
[46] DAI L, ZHENG T, XU K, et al. A universal design of betacoronavirus vaccines against COVID-19, MERS, and SARS[J]. Cell, 2020, 182(3): 722-733.
[47] GAO Q, BAO L, MAO H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2[J]. Science, 2020, 69(6499): 77-81.
[48] GEALL A J, VERMA A, OTTEN G R, et al. Nonviral delivery of self-amplifying RNA vaccines[J]. Proc Natl Acad Sci USA, 2012, 109(36): 14604-14609.
[49] LUNG P, YANG J, LI Q. Nanoparticle formulated vaccine: opportunities and challenges[J]. Nanoscale, 2020, 12(10): 5746-5763.
[50] SAHIN U, MUIK A, DERHOVANESSIAN E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses[J]. Nature, 2020, 586(7830): 594-599.
[51] Nanomedicine and the COVID-19 vaccines[J]. Nat Nanotechnol, 2020, 15(12): 963.
[52] KRAMMER F. SARS-CoV-2 vaccines in development[J]. Nature, 2020, 586(7830): 516-527.
[53] CHAUHAN G, MADOU M J, KALRA S, et al. Nanotechnology for COVID-19: therapeutics and vaccine research[J]. ACS Nano, 2020, 14(7): 7760-7782.
[54] GALLUCCI S, MATZINGER P. Danger signals: SOS to the immune system[J]. Curr Opin Immunol, 2001, 13(1): 114-119.
[55] 黄少梅. 功能性碳点抗病毒药物与免疫佐剂的研究[D]. 华中农业大学, 2019.
HUANG S M. The development of functional carbon dots in antiviral and adjuvant agents[D]. Huazhong Agricultural University, 2019.
[56] 许利耕, 陈春英. 纳米材料作为重大疾病疫苗载体或佐剂的研究进展[J]. 科学通报, 2012, 57(25): 2341-2353.
XU L G, CHEN C Y. Recent advances on nanomaterials as vaccine carriers and adjuvants for major diseases[J]. Chinese Sci Bull, 2012, 57: 2341-2353.
[57] 苏新, 闫丹, 杨云裳. 多孔硅纳米材料作为疫苗载体和佐剂研究进展[J]. 中兽医医药杂志, 2017, 36(1): 20-23.
SU X, YAN D, YANG Y S. Progress of nano-porous silicon as adjuvants or carrier in vaccine[J]. JTCVM, 2017, 36(1): 20-23.
[58] 张蜜. 用于无针注射疫苗的纳米载药系统的初步研究[D]. 华中科技大学, 2008.
ZHANG M. A preliminary study on nano vaccine delivery system intended for needle free injections[D]. Huazhong University of Science and Technology, 2008.
[59] 何萍, 吕凤林, 陈月,等. 纳米铝佐剂吸附HBsAg及其免疫学效应的研究[J]. 高等学校化学学报, 2005, 26(5): 886-888.
HE P, LV F L, CHEN Y, et al. Immune effect of HBsAg adsorbed by nanoparticulate alum adjuvant[J]. Chem J Chinese Univ, 2005, 26(5): 886-888.
[60] DAMM D, ROJAS S L, THEOBALD H, et al. Calcium phosphate nanoparticle-based vaccines as a platform for improvement of HIV-1 Env antibody responses by intrastructural help[J]. Nanomaterials, 2019, 9(10): 1389.
[61] WOHIFAT S, KHALANSKY A S, GELPERINA S, et al. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier[J]. J Controlled Release, 2011, 154(1): 103-107.
[62] MALHOTRA M, PRAKASH S. Targeted drug delivery across blood-brain-barrier using cell penetrating peptides tagged nanoparticles[J]. Curr Nanosci, 2011, 7(1): 81-93.
[63] DONG J, SHANG Y, TIAN L, et al. Detailed deposition analysis of inertial and diffusive particles in a rat nasal passage[J]. Inhalation Toxicol, 2018, 30(1): 29-39.

Application of Nano Biomaterials in Antiviral Vaccine Adjuvant

PDF

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 3

Recommended Articles

Metrics

Comments

[1]	ZHAO Yue, MENG Xiang-Qin, YAN Xi-Yun, FAN Ke-Long. Nanozyme: A New Type of Biosafety Material [J]. Chinese Journal of Applied Chemistry, 2021, 38(5): 524-545.
[2]	XIA Lijuan, WANG Xiaobin, XIE Yan, WANG Xiaoyan, XIAO Wei, ZHONG Xinming, HUANG Minguo, XUE Wei. Synthesis and Biological Activity of Novel 1,4-Pentadien-3-one Oxime Esters Bearing Heterocycle Moiety [J]. Chinese Journal of Applied Chemistry, 2017, 34(3): 316-323.
[3]	WEI Qiang, LIU Jie. Chemical Components of the Essential Oils of Leaf, Stem and Fruit from Euonymus japonicus Thunb. and Their Antiviral Activities [J]. Chinese Journal of Applied Chemistry, 2016, 33(6): 719-726.